Telephone
1.952.818.8400
Address
400 Gateway Boulevard Burnsville, MN 55337
Description
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The firm offers the Advantage-MR EP Recorder/Stimulator system, an electrophysiology amplifier and recording system with integrated cardiac stimulator, Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter, and Vision-MR Dispersive Electrode, an ablation dispersive electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. The company was founded by Steven Wedan in 2006 and is headquartered in Burnsville, MN.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.18 - 0.83
Trade Value (12mth)
AU$14,339.00
1 week
-2.59%
1 month
-5.83%
YTD
56.94%
1 year
46.75%
All time high
2.94
EPS 3 yr Growth
-16.400%
EBITDA Margin
%
Operating Cashflow
-$24m
Free Cash Flow Return
-97.50%
ROIC
-102.50%
Interest Coverage
-93.00
Quick Ratio
3.60
Shares on Issue (Fully Dilluted)
151m
HALO Sector
Healthcare
Next Company Report Date
21-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Imricor Q3 FY23 Quarterley Activities Report and Appendix 4C
×
Imricor Q3 FY23 Quarterley Activities Report and Appendix 4C |
31 August 22 |
Appendix 4D and Half Year Report & Accounts
×
Appendix 4D and Half Year Report & Accounts |
31 August 22 |
Imricor releases Half Year Results for 1H 2022
×
Imricor releases Half Year Results for 1H 2022 |
31 August 22 |
H1 FY22 Results Investor Presentation
×
H1 FY22 Results Investor Presentation |
29 September 23 |
Funding Facility Drawdown
×
Funding Facility Drawdown |
29 September 23 |
Proposed issue of securities - IMR
×
Proposed issue of securities - IMR |
29 March 23 |
Notification regarding unquoted securities - IMR
×
Notification regarding unquoted securities - IMR |
29 August 23 |
Becoming a substantial holder
×
Becoming a substantial holder |
29 April 22 |
Imricor to Present at NWR Virtual Conference
×
Imricor to Present at NWR Virtual Conference |
28 September 23 |
Change of Registered Address in Australia
×
Change of Registered Address in Australia |
28 November 23 |
Joint Development Agreement with ADIS for AI Modules
×
Joint Development Agreement with ADIS for AI Modules |
28 March 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
28 June 22 |
Imricor Signs Siemens Agreements and Businss Update
×
Imricor Signs Siemens Agreements and Businss Update |
28 June 22 |
Change in substantial holding
×
Change in substantial holding |
28 July 22 |
Appendix 4C - Quarterly Report and Business Update
×
Appendix 4C - Quarterly Report and Business Update |
28 January 22 |
Details of FY21 Results Investor Briefing
×
Details of FY21 Results Investor Briefing |
28 April 22 |
Updated Corporate Goverance Statement
×
Updated Corporate Goverance Statement |
28 April 22 |
Appendix 4C - Quarterly Report and Business Update
×
Appendix 4C - Quarterly Report and Business Update |
27 October 22 |
Imricor Q3 FY22 Quarterley Activities Report and Appendix 4C
×
Imricor Q3 FY22 Quarterley Activities Report and Appendix 4C |
27 October 22 |
Investor Presentation
×
Investor Presentation |
27 July 23 |
Imricor Q2 FY23 Quarterley Activities Report and Appendix 4C
×
Imricor Q2 FY23 Quarterley Activities Report and Appendix 4C |
27 January 23 |
Imricor and GE HealthCare MOU for Collaboration
×
Imricor and GE HealthCare MOU for Collaboration |
27 January 22 |
Appendix 4C - Quarterly Report and Business Update
×
Appendix 4C - Quarterly Report and Business Update |
27 April 23 |
Imricor Q1 FY23 Quarterley Activities Report and Appendix 4C
×
Imricor Q1 FY23 Quarterley Activities Report and Appendix 4C |
26 September 23 |
Approval to Commence VISABL-VT Trial in Germany
×
Approval to Commence VISABL-VT Trial in Germany |
26 November 20 |
Imricor to Present at Bell Potter Healthcare Conference
×
Imricor to Present at Bell Potter Healthcare Conference |
26 May 23 |
Release from Voluntary Escrow
×
Release from Voluntary Escrow |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.